Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific...
Reexamination Certificate
2005-11-09
2010-11-16
Le, Emily M. (Department: 1648)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
Reexamination Certificate
active
07833538
ABSTRACT:
The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
REFERENCES:
patent: 5149798 (1992-09-01), Agrawal et al.
patent: 6077833 (2000-06-01), Bennett et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: WO 94/22892 (1994-10-01), None
patent: WO99/62923 (1999-12-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO-9962923 (1999-12-01), None
U.S. Appl. No. 09/965,116, by Ekambar Kandimalla, Qiuyan Zhao, Dong Yu and Sudhir Agrawal, filed Sep. 26, 2001.
U.S. Appl. No. 10/694,418, by Ekambar Kandimalla, Qiuyan Zhao, Dong Yu and Sudhir Agrawal, filed Oct. 27, 2003.
U.S. Appl. No. 10/694,383, by Ekambar Kandimalla, Qiuyan Zhao, Dong Yu and Sudhir Agrawal, filed Oct. 27, 2003.
U.S. Appl. No. 10/694,586, by Ekambar Kandimalla, Qiuyan Zhao, Dong Yu and Sudhir Agrawal, filed Oct. 27, 2003.
U.S. Appl. No. 10/694,075, by Ekambar Kandimalla, Qiuyan Zhao, Dong Yu and Sudhir Agrawal, filed Oct. 27, 2003.
U.S. Appl. No. 10/694,207, by Ekambar Kandimalla, Qiuyan Zhao, Dong Yu and Sudhir Agrawal, filed Oct. 27, 2003.
Khorana et al., “Studies on Polynucleotides”, J. Molec. Biol. 72:209 (1972).
Reese et al., “The Chemical Synthesis of Oligo-and Poly-Nucleotides by the Phosporotriester Approach”, Tetrahedron 34:3143-3179 (1978).
Beaucage et al., “Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotide Synthesis”, Tetrahedron lett. 22:1859-1862 (1981).
Connolly et al., “Synthesis and Characterization of an Octanucleotide Containing the EcoRI Recognition Sequence with a Phosphorothioate Group at the Cleavage Site”, Biochemistry 23:3443 (1984).
Agrawal et al., “Oligodeoxynucleotise Methylphosphonates: Synthesis and Enzymic Degradation”, Tetrahedron Lett. 28(31):3539-3542 (1987).
Jager et al., “Oligonucleotide N-Alkylphosphoroamidates: Synthesis and Binding to Polynucleotides”, Biochemistry 27:7237 (1988).
Agrawal et al., “Oligodeoxynucleoside Phosphoramidites and Phosphorothioate as Inhibitors of Human Immunodeficiency Virus”, Proc. Natl. Acad. Sci. USA 85:7079-7083 (1988).
Zon et al., “Phosphorothioate Oligonucleotides” Oligonucleotides and Analogs: A Practical Approach, 87-108 (1991).
Kuramoto et al., “Oligonucleotide Sequences Required for Natural Killer Cell Activation”, Jpn. J. Cancer Res. 83:1128-1131 (1992).
Crooke et al., “An Overview of Profess in Antisense Therapeutics”, Antisense * Nucl. Acid Drug Dev. 115-122 CRC Press, Boca Raton, Florida (1993).
Zon, “Protocols for Oligonucleotides and Analogs”, Methods in Mol. Biol. 20:165-189 (1993).
Pisetsky et al., “Stimulation of Murine Lymphocyte Proliferation by a Phosphorothioate Oligonucleotide with Antisense Activity for Herpes Simplex Virus”, Life Science 54:101 (1994).
Yamamoto et al., Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence of AACGTT to Murine Spenocytes Enhance Interferon Production and Natural Killer Activity, Microbiology Immunol. 38:831 (1994).
Agrawal et al., Modified Oligonucleotides as Therapeutic and Diagnostic Agents, Curr. Opin. Biotechnol. 6:12-19 (1995).
Krieg et al., “CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation” Nature 371:546-549 (1995).
Klinman et al., “CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Interleukin 12, and Interferon y” Proc. Natl. Acad. Sci. USA 93:2879 (1996).
Liang et al., “Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides” J. Clin. Invest. 98:1119-1129 (1996).
Zhao et al., “Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation” Biochem. Pharm. 51:173-182 (1996).
Chu et al., “CpG Oligodeoxynucleotides Acts as Adjuvants that Switch on T Helper 1 (TH1) Immunity”, J. Exp. Med. 186:1623 (1997).
Dunford et al., “Antisense 97:Targeting the Molecular Basis of Disease” (Nature Biotechnology) Conference Abstract pp. 40 (1997).
Sparwasser et al., “Macrophages Sense Pathogens Via DNA Motifs: Induction of Tumor Necrosis Factor-α-Mediated Shock” Eur. J. Immunol. 27:1671 (1997).
Zhao et al., “pattern and Kinetics of cytokine Production Following Administration of Phosphorothioate Oligonucleotides in Mice” Antisense Nucleic Acid Drug Dev. 7:495 (1997).
McCluskie et al., “cutting Edge: CpG DNA is a Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice”, J. Immunol. 161:4463-4466 (1998).
Moldoveanu et al., “CpG DNA, A novel Immune enhancer for Systemic and Mucosal Immunization with Influenza Virus”, Vaccine 16:1216-1224 (1998).
Sparwasser et al., “Bacterial DNA and Immunostimulatory CpG Oligonucleotides Trigger Maturation and Activation of Murine Dendritic Cells” 28:2045 (1998).
Tokunaga et al., “How CG Led to the Discovery of Immunostimulatory DNA” Jap. J. Infect. Dis. 1 (1999).
Zhao et al., “Site of chemical Modifications in CpG Containing Phosphorothioate Oligodeoxynucleotide Modulates its Immunostimulatory Activity” Bioorg. & med. Chem. Lett. 9:3453-3458 (1999).
Agrawal et al., “Antisense Therapeutics: Is it as Simple as Complementary Base Recognition”, Mol. Med. Today 6:72 (2000).
Zhao et al., “Immunostimulatory Activity of CpG Containing Phosphorotioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside” Bioorg. & med. Chem. Lett. 10:1051-1054 (2000).
Agrawal et al., “Antisense Therapeutics”, Curr. Opin. Chem. Biol. 2:519-528 (1998).
Chaix et al., “3-3′ Linked Oligonucleotides: Synthesis and Stability Studies” Bioorg. & med. Chem. 6:827-832 (1996).
Klinman et al., “Therapeutic Applications of CpG-Containing Oligodeoxynucleotides” Antisense & Nucl. Acid Drug Rev. 8:181-184 (1998).
Yu et al., “Accessible 5′-end of CpG containing Phosphorothioate Oligodeoxynucleotides is essential for immunostimulatory activity.” Bioorganic & Medicinal Chemistry Lett. 10:2585-2588 (2000).
Kandimalla et al., “Effect of chemical modifications of cytosine and guanine in a CpG motif of oligonucleotides: Structure-Immunostimulatory Activity relationships . . . ” Bioorg. & Med. Chem. 9:807-813 (2001).
Agrawal Sudhir
Kandimalla Ekambar R.
Yu Dong
Zhao Qiuyan
Flaherty Preti
Idera Pharmaceuticals Inc.
Keown Wayne A
Le Emily M.
LandOfFree
Modulation of immunostimulatory activity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of immunostimulatory activity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of immunostimulatory activity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4170318